Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.

被引：0
|
作者：
Ward, TH
Danson, S
Dawson, M
McGrath, H
Denneny, O
Cummings, J
Dive, C
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[3] Canc Res UK, Drug Dev Off, London, England
来源：
BRITISH JOURNAL OF CANCER | 2004年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [31] Immunological evaluation of personalized peptide vaccination for patients with malignant glioma: The results of a clinical phase I trial.
    Yamanaka, R.
    Yajima, N.
    Mine, T.
    Yamada, A.
    Shigemor, M.
    Ito, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 64S - 64S
  • [32] Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment
    Reboldi, Gianpaolo
    Gentile, Giorgio
    Angeli, Fabio
    Verdecchia, Paolo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (01) : 115 - 128
  • [33] PHASE I/II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN
    GILL, PS
    ESPINA, BM
    MUGGIA, F
    CABRIALES, S
    TULPULE, A
    ESPLIN, JA
    LIEBMAN, HA
    FORSSEN, E
    ROSS, ME
    LEVINE, AM
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 996 - 1003
  • [34] Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
    Y Matsumura
    T Hamaguchi
    T Ura
    K Muro
    Y Yamada
    Y Shimada
    K Shirao
    T Okusaka
    H Ueno
    M Ikeda
    N Watanabe
    British Journal of Cancer, 2004, 91 : 1775 - 1781
  • [35] Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
    Matsumura, Y
    Hamaguchi, T
    Ura, T
    Muro, K
    Yamada, Y
    Shimada, Y
    Shirao, K
    Okusaka, T
    Ueno, H
    Ikeda, M
    Watanabe, N
    BRITISH JOURNAL OF CANCER, 2004, 91 (10) : 1775 - 1781
  • [36] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial
    Priyanga Ranasinghe
    Ranil Jayawardena
    Shehani Pigera
    Wasundara Sevwandi Wathurapatha
    Hasitha Dhananjaya Weeratunga
    G. A. Sirimal Premakumara
    Prasad Katulanda
    Godwin Roger Constantine
    Priyadarshani Galappaththy
    BMC Complementary and Alternative Medicine, 17
  • [37] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial
    Ranasinghe, Priyanga
    Jayawardena, Ranil
    Pigera, Shehani
    Wathurapatha, Wasundara Sevwandi
    Weeratunga, Hasitha Dhananjaya
    Premakumara, G. A. Sirimal
    Katulanda, Prasad
    Constantine, Godwin Roger
    Galappaththy, Priyadarshani
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [38] Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy
    Hurst, AK
    Shotan, A
    Hoffman, K
    Johnson, J
    Goodwin, TM
    Koda, R
    Elkayam, U
    PHARMACOTHERAPY, 1998, 18 (04): : 840 - 846
  • [39] Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane
    Schilling, T
    Keppler, KB
    Heim, ME
    Niebch, G
    Dietzfelbinger, H
    Rastetter, J
    Hanauske, AR
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (04) : 327 - 332
  • [40] Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
    Quintela-Fandino, Miguel
    Apala, Juan V.
    Malon, Diego
    Mouron, Silvana
    Hornedo, Javier
    Gonzalez-Cortijo, Lucia
    Colomer, Ramon
    Guerra, Juan
    BREAST CANCER RESEARCH, 2019, 21
12345